Inadvertent Administration of 72 µg of Follitropin-Δ for Three Consecutive Days Does Not Appear to Be Dangerous for Poor Responders: A Case Series
Abstract
:1. Introduction
2. Case Series Presentation
2.1. Case 1
Medical History of the Patient
2.2. Case 2
Medical History of the Patient
2.3. Case 3
Medical History of the Patient
2.4. Case 4
Medical History of the Patient
3. Methods
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Koechling, W.; Plaksin, D.; E Croston, G.; Jeppesen, J.V.; Macklon, K.T.; Andersen, C.Y. Comparative pharmacology of a new recombinant FSH expressed by a human cell line. Endocr. Connect. 2017, 6, 297–305. [Google Scholar] [CrossRef] [PubMed]
- Andersen, A.N.; Nelson, S.M.; Fauser, B.C.; García-Velasco, J.A.; Klein, B.M.; Arce, J.-C.; Tournaye, H.; De Sutter, P.; Decleer, W.; Petracco, A.; et al. Individualized versus conventional ovarian stimulation for in vitro fertilization: A multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertil. Steril. 2017, 107, 387–396.e4. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Longobardi, S.; Seidler, A.; Martins, J.; Beckers, F.; MacGillivray, W.; D’hooghe, T. An evaluation of the use and handling errors of currently available recombinant human follicle-stimulating hormone pen injectors by women with infertility and fertility nurses. Expert Opin. Drug Deliv. 2019, 16, 1003–1014. [Google Scholar] [CrossRef] [PubMed]
- Fernández-Sánchez, M.; Visnova, H.; Yuzpe, A.; Klein, B.M.; Mannaerts, B.; Arce, J.-C. Individualization of the starting dose of follitropin delta reduces the overall OHSS risk and/or the need for additional preventive interventions: Cumulative data over three stimulation cycles. Reprod. Biomed. Online 2019, 38, 528–537. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- La Marca, A.; Tolani, A.D.; Capuzzo, M. The interchangeability of two assays for the measurement of anti-Mullerian hormone when personalizing the dose of FSH in in-vitro fertilization cycles. Gynecol. Endocrinol. 2021, 37, 372–376. [Google Scholar] [CrossRef]
- Bissonnette, F.; Masip, J.M.; Kadoch, I.-J.; Librach, C.; Sampalis, J.; Yuzpe, A. Individualized ovarian stimulation for in vitro fertilization: A multicenter, open label, exploratory study with a mixed protocol of follitropin delta and highly purified human menopausal gonadotropin. Fertil. Steril. 2021, 115, 991–1000. [Google Scholar]
- Iliodromiti, S.; Salje, B.; Dewailly, D.; Fairburn, C.; Fanchin, R.; Fleming, R.; Li, H.W.R.; Lukaszuk, K.; Ng, E.H.Y.; Pigny, P.; et al. Non-equivalence of anti-Mullerian hormone automated assays-clinical implications for use as a companion diagnostic for individualised gonadotrophin dosing. Hum. Reprod. 2017, 32, 1710–1715. [Google Scholar] [CrossRef] [Green Version]
- Doroftei, B.; Ilie, O.-D.; Anton, N.; Marcu, O.-A.; Scripcariu, I.-S.; Ilea, C. A Narrative Review Discussing the Efficiency of Personalized Dosing Algorithm of Follitropin Delta for Ovarian Stimulation and the Reproductive and Clinical Outcomes. Diagnostics 2023, 13, 177. [Google Scholar] [CrossRef] [PubMed]
- Doroftei, B.; Ilie, O.-D.; Anton, N.; Marcu, O.-A.; Scripcariu, I.-S.; Ilea, C. Anti-Mullerian hormone variability and its implications for the number of oocytes retrieved following individualized dosing with follitropin delta. Clin. Endocrinol. 2019, 90, 719–726. [Google Scholar]
- Višnová, H.; Papaleo, E.; Martin, F.S.; Koziol, K.; Klein, B.M.; Mannaerts, B. Clinical outcomes of potential high responders after individualized FSH dosing based on anti-Mullerian hormone and body weight. Reprod. Biomed. Online 2021, 43, 1019–1026. [Google Scholar] [CrossRef]
- Bachmann, A.; Kissler, S.; Laubert, I.; Mehrle, P.; Mempel, A.; Reissmann, C.; Sauer, D.S.; Tauchert, S.; Bielfeld, A.P. An eight centre, retrospective, clinical practice data analysis of algorithm-based treatment with follitropin delta. Reprod. Biomed. Online 2022, 44, 853–857. [Google Scholar] [CrossRef] [PubMed]
- Arab, S.; Frank, R.; Ruiter, J.; Dahan, M.H. How to dose follitropin delta for the first insemination cycle according to the ESHRE and ASRM guidelines; a retrospective cohort study. J. Ovarian Res. 2023, 16, 24. [Google Scholar] [CrossRef] [PubMed]
- Doroftei, B.; Ilie, O.-D.; Dabuleanu, A.-M.; Diaconu, R.; Maftei, R.; Simionescu, G.; Ilea, C. Follitropin Delta as a State-of-the-Art Incorporated Companion for Assisted Reproductive Procedures: A Two Year Observational Study. Medicina 2021, 57, 379. [Google Scholar] [CrossRef] [PubMed]
- Haakman, O.; Liang, T.; Murray, K.; Vilos, A.; Vilos, G.; Bates, C.; Watson, A.J.; Miller, M.R.; Abu-Rafea, B. In vitro fertilization cycles stimulated with follitropin delta result in similar embryo development and quality when compared with cycles stimulated with follitropin alfa or follitropin beta. F&S Rep. 2021, 2, 30–35. [Google Scholar]
- Qiao, J.; Zhang, Y.; Liang, X.; Ho, T.; Huang, H.-Y.; Kim, S.-H.; Goethberg, M.; Mannaerts, B.; Arce, J.-C. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients. Hum. Reprod. 2021, 36, 2452–2462. [Google Scholar] [CrossRef]
- Yang, R.; Zhang, Y.; Liang, X.; Song, X.; Wei, Z.; Liu, J.; Yang, Y.; Tan, J.; Zhang, Q.; Sun, Y.; et al. Comparative clinical outcome following individualized follitropin delta dosing in Chinese women undergoing ovarian stimulation for in vitro fertilization/intracytoplasmic sperm injection. Reprod. Biol. Endocrinol. 2022, 20, 147. [Google Scholar] [CrossRef]
- Ishihara, O.; Nelson, S.M.; Arce, J.-C. Comparison of ovarian response to follitropin delta in Japanese and White IVF/ICSI patients. Reprod. Biomed. Online 2022, 44, 177–184. [Google Scholar] [CrossRef]
- Blockeel, C.; Griesinger, G.; Rago, R.; Larsson, P.; Sonderegger, Y.L.Y.; Rivière, S.; Laven, J.S.E. Prospective Multicenter Non-Interventional Real-World Study to Assess the Patterns of Use, Effectiveness and Safety of Follitropin Delta in Routine Clinical Practice (the PROFILE Study). Front. Endocrinol. 2022, 13, 992677. [Google Scholar] [CrossRef]
- REKOVELLE, INN-Follitropin Delta. Available online: https://www.ema.europa.eu/en/documents/product-information/rekovelle-epar-product-information_en.pdf (accessed on 20 June 2023).
- Ishihara, O.; Arce, J.C.; Japanese, G. Follitropin Delta Phase 3 Trial, Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: A randomized controlled trial. Reprod. Biomed. Online 2021, 42, 909–918. [Google Scholar] [CrossRef]
- Yacoub, S.; Cadesky, K.; Casper, R.F. Low risk of OHSS with follitropin delta use in women with different polycystic ovary syndrome phenotypes: A retrospective case series. J. Ovarian Res. 2021, 14, 31. [Google Scholar] [CrossRef]
- Sánchez, M.F.; Višnová, H.; Larsson, P.; Andersen, C.Y.; Filicori, M.; Blockeel, C.; Pinborg, A.; Khalaf, Y.; Mannaerts, B.; de Sutter, P.; et al. A randomized, controlled, first-in-patient trial of choriogonadotropin beta added to follitropin delta in women undergoing ovarian stimulation in a long GnRH agonist protocol. Hum. Reprod. 2022, 37, 1161–1174. [Google Scholar] [CrossRef] [PubMed]
- Montenegro Gouveia, S.; Lispi, M.; D’Hooghe, T.M. Comparison between follitropin-delta and follitropin-alfa for ovarian stimulation in context of ART is only scientifically sound and clinically relevant if individualization of starting dose is allowed in both arms! Reprod. Biomed. Online 2022, 45, 623–624. [Google Scholar] [CrossRef] [PubMed]
- Kovacs, P.; Jayakumaran, J.; Lu, Y.; Lindheim, S.R. Comparing pregnancy rates following ovarian stimulation with follitropin-Delta to follitropin -alpha in routine IVF: A retrospective analysis. Eur. J. Obstet. Gynecol. Reprod. Biol. 2023, 280, 22–27. [Google Scholar] [CrossRef] [PubMed]
- Havelock, J.; Aaris Henningsen, A.K.; Mannaerts, B.; Arce, J.C.; ESTHER-1 and ESTHER-2 Trial Groups. Pregnancy and neonatal outcomes in fresh and frozen cycles using blastocysts derived from ovarian stimulation with follitropin delta. J. Assist. Reprod. Genet. 2021, 38, 2651–2661. [Google Scholar] [CrossRef] [PubMed]
- Arce, J.C.; Larsson, P.; Garcia-Velasco, J.A. Establishing the follitropin delta dose that provides a comparable ovarian response to 150 IU/day follitropin alfa. Reprod. Biomed. Online 2020, 41, 616–622. [Google Scholar] [CrossRef] [PubMed]
- Shao, F.; Jiang, Y.; Ding, S.; Larsson, P.; Pinton, P.; Jonker, D.M. Pharmacokinetics and Safety of Follitropin Delta in Gonadotropin Down-Regulated Healthy Chinese Women. Clin. Drug Investig. 2023, 43, 37–44. [Google Scholar] [CrossRef]
- Bosch, E.; Havelock, J.; Martin, F.S.; Rasmussen, B.B.; Klein, B.M.; Mannaerts, B.; Arce, J.-C. Follitropin delta in repeated ovarian stimulation for IVF: A controlled, assessor-blind Phase 3 safety trial. Reprod. Biomed. Online 2019, 38, 195–205. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Baldini, D.; Baldini, A.; Silvestris, E.; Vizziello, G.; Ferri, D.; Vizziello, D. A fast and safe technique for sperm preparation in ICSI treatments within a randomized controlled trial (RCT). Reprod. Biol. Endocrinol. 2020, 18, 88. [Google Scholar] [CrossRef]
- Malvasi, A.; Baldini, D. Pick up and Oocyte Management; Springer: Berlin/Heidelberg, Germany, 2020. [Google Scholar]
- Baldini, D.; Savoia, M.V.; Sciancalepore, A.G.; Malvasi, A.; Vizziello, D.; Beck, R.; Vizziello, G. High progesterone levels on the day of HCG administration do not affect the embryo quality and the reproductive outcomes of frozen embryo transfers. La Clin. Ter. 2018, 169, e91–e95. [Google Scholar]
- Baldini; Beck, R.; Negro, F.; De Viti, D. Assisted reproductive technologies and metabolic syndrome complications: Medico-legal reappraisal. La Clin. Ter. 2019, 170, e364–e367. [Google Scholar]
- Baldini, D.; Ferri, D.; Baldini, G.M.; Lot, D.; Catino, A.; Vizziello, D.; Vizziello, G. Sperm Selection for ICSI: Do We Have a Winner? Cells 2021, 10, 3566. [Google Scholar] [CrossRef] [PubMed]
- Ishihara, O.; Klein, B.M.; Arce, J.C.; Kuramoto, T.; Yokota, Y.; Mukaida, T.; Kokeguchi, S.; Ishikawa, M.; Oku, H.; Japanese Follitropin Delta Phase 2 Trial Group; et al. Randomized, assessor-blind, antimullerian hormone-stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertil. Steril. 2021, 115, 1478–1486. [Google Scholar] [CrossRef] [PubMed]
Organ Class | Common | Uncommon |
---|---|---|
Psychiatric disorders and nervous system disorders | Headache | Mood swings, dizziness, and drowsiness |
Gastrointestinal pathologies | Nausea | Diarrhea, vomiting, abdominal discomfort, and constipation |
Reproductive system diseases and mammary pathologies | Discomfort of the pelvic area and uterine appendages | Vaginal bleeding, breast tenderness and pain |
General disorders and administration site conditions | Fatigue |
Case 1 | Case 2 | Case 3 | Case 4 | |
---|---|---|---|---|
Age (yrs) | 36 | 41 | 35 | 38 |
Body mass index (BMI) | 24.4 | 26.9 | 22.9 | 19.5 |
Diagnosis | Reduced ovarian reserve Fertility preservation | Reduced ovarian reserve | Reduced ovarian reserve Fertility preservation | Recurrent miscarriages |
Parity | 0/0/0/0 | 0/0/0/0 | 0/0/0/0 | 0/0/3/0 |
Blood type | 0+ | 0+ | 0+ | 0+ |
Antithrombin III % | 91 | 91 | 91 | 91.3 |
C-Protein % | 85 | 85 | 85 | 97 |
S-Protein % | 94 | 94 | 94 | 55 |
Anti-Cardiolipin IgG | Normal | Normal | Normal | Normal |
Lupus anticoagulants | Normal | Normal | Normal | Normal |
Factor V Leiden | Normal | Normal | Normal | Normal |
Factor II | Normal | Normal | Normal | Normal |
TSH | 0.87 | 2.01 | 1.62 | 1.84 |
Basal E2 (pmol/L) | 81 | 101 | 72 | 58 |
Basal FSH (IU) | 11.6 | 14.6 | 9.2 | 8.7 |
Basal P4 (nmol/L) | 0.35 | 0.24 | 0.42 | 0.37 |
Antral follicle count (AFC) | 8 | 6 | 7 | 3 |
AMH | 0.64 | 0.19 | 0.75 | 0.11 |
Vitamin D | 28 | 28 | 28 | 32 |
Case 1 | Case 2 | Case 3 | Case 4 | |
---|---|---|---|---|
Date of stimulation | 28 June 2019 | 5 September 2021 | 21 June 2021 | 30 June 2021 |
Data fine stimulation | 6 July 2019 | 16 September 2021 | 3 July 2021 | 14 July 2021 |
Total FSH (µg) | 336 | 406 | 406 | 436 |
Number of follicles at the end of stimulation (n) | 4 | 5 | 4 | 3 |
Endometrium thickness (mm) | 8.4 | 8.5 | 8.1 | 7.9 |
Number of oocytes retrieved (n) | 4 | 4 | 4 | 1 |
Number of MII oocytes (n) | 4 | 3 | 3 | 1 |
Number of MII oocytes cryopreserved | 4 | - | 3 | - |
Number of embryos obtained (n) | - | 1 | - | 1 |
Number of embryos transferred (n) | - | 1 | - | 1 |
Pregnancy | - | No | - | No |
Case 1 | Case 2 | Case 3 | Case 4 | |
---|---|---|---|---|
Serum Estradiol (pg/mL) | 261 | 165 | 89 | 104 |
Serum Progesterone (ng/mL) | 0.75 | 0.81 | 0.62 | 0.71 |
Abdominal ultrasonography | Normal | Normal | Normal | Normal |
Blood pressure (mmHg) | 130/85 | 110/75 | 125/85 | 120/80 |
Electrocardiography | Normal | Normal | Normal | Normal |
GOT and GPT (U/L) | 23–28 | 25–29 | 22–28 | 25–27 |
Alkaline phosphatase (U/L) | 160 | 180 | 172 | 155 |
Azotemia (mg/dL) | 40 | 39 | 44 | 42 |
Creatininemia (mg/dL) | 0.93 | 0.91 | 0.87 | 0.83 |
Glomerular filtration rate (mL/min) | 95 | 92 | 94 | 90 |
Blood sugar (mg/dL) | 89 | 82 | 92 | 91 |
PT (Inr) | 1 | 0.97 | 0.98 | 0.95 |
PTT (s) | 32 | 32 | 34 | 31 |
Antithrombin III (%) | 94 | 89 | 97 | 92 |
D-dimer (ng/mL) | 410 | 387 | 390 | 381 |
Side effects | Mild headache | Mild nausea | - | - |
Adverse reactions | - | - | - | - |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Baldini, G.M.; Mastrorocco, A.; Sciorio, R.; Palini, S.; Dellino, M.; Cascardi, E.; Cazzato, G.; Malvasi, A.; Baldini, D.; Trojano, G. Inadvertent Administration of 72 µg of Follitropin-Δ for Three Consecutive Days Does Not Appear to Be Dangerous for Poor Responders: A Case Series. J. Clin. Med. 2023, 12, 5202. https://doi.org/10.3390/jcm12165202
Baldini GM, Mastrorocco A, Sciorio R, Palini S, Dellino M, Cascardi E, Cazzato G, Malvasi A, Baldini D, Trojano G. Inadvertent Administration of 72 µg of Follitropin-Δ for Three Consecutive Days Does Not Appear to Be Dangerous for Poor Responders: A Case Series. Journal of Clinical Medicine. 2023; 12(16):5202. https://doi.org/10.3390/jcm12165202
Chicago/Turabian StyleBaldini, Giorgio Maria, Antonella Mastrorocco, Romualdo Sciorio, Simone Palini, Miriam Dellino, Eliano Cascardi, Gerardo Cazzato, Antonio Malvasi, Domenico Baldini, and Giuseppe Trojano. 2023. "Inadvertent Administration of 72 µg of Follitropin-Δ for Three Consecutive Days Does Not Appear to Be Dangerous for Poor Responders: A Case Series" Journal of Clinical Medicine 12, no. 16: 5202. https://doi.org/10.3390/jcm12165202
APA StyleBaldini, G. M., Mastrorocco, A., Sciorio, R., Palini, S., Dellino, M., Cascardi, E., Cazzato, G., Malvasi, A., Baldini, D., & Trojano, G. (2023). Inadvertent Administration of 72 µg of Follitropin-Δ for Three Consecutive Days Does Not Appear to Be Dangerous for Poor Responders: A Case Series. Journal of Clinical Medicine, 12(16), 5202. https://doi.org/10.3390/jcm12165202